Comparing the current results to its competitors, Aligos Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 809.97 % year on year. The sales growth was above Aligos Therapeutics Inc 's competitors' average revenue growth of 118.68 %, achieved in the same quarter.
Aligos Therapeutics Inc , slower than the average decrease reported by the company's competitors of -22.8 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -22.8 %
Due to outstanding performance in Overall company, revenue grew by 809.97 % Aligos Therapeutics Inc improved its market share, to approximately 0.02 %.
November 19, 2024
Aligos Therapeutics Advances Hepatic Therapeutics with Landmark Discoveries in 2024 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical organization pioneering the landscape of liver and viral disease therapeutics, marked a significant year of progress in 2024 with impactful presentations and poignant moments at major international hepatitis research conferences. The company s groundbreaking research, showcased at The Liver Meeting 2024 and the European Association for the Study of the Liver (EASL) Congress 2024, underscores its commitment to addressing critical unmet medical needs. Breakthroughs at The Liver Meeting 2024 During the American Association for the Study of Liver Disease...
June 5, 2024
Positive Data Presented by Aligos Therapeutics at EASL Congress 2024 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for liver and viral diseases, presented encouraging data at the European Association for the Study of the Liver (EASL) Congress 2024. The congress, which took place from June 5-8 in Milan, Italy, featured six poster presentations by Aligos, showcasing their advancements in therapeutic solutions. Details of the Presentation The data presented at the EASL Congress highlighted multiple aspects of Aligos Therapeutics ongoing research and development projects. 1. Innovative Therapies for Chronic Hepatitis B : Ali...
April 3, 2024
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease characterized by the presence of fat, inflammation, and liver cell damage in individuals with metabolic dysfunction, such as obesity, type 2 diabetes, and dyslipidemia. Aiming to address the unmet medical needs of MASH patients, Aligos Therapeutics, a clinical stage biopharmaceutical company, has recently initiated the Phase 2a HERALD study of ALG-055009. In this article, we discuss the significance of this study and its potential implications in the treatment of MASH.Background:MASH is a growing public health concern, affecting millions of individuals worldwide. The disease can progress to advanced fibrosis and cirrhosis,...
March 27, 2024
Aligos Therapeutics, a leading biopharmaceutical company, recently presented groundbreaking clinical data at the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2024, held in Kyoto, Japan. With a primary focus on developing novel therapeutics targeting liver and viral diseases, Aligos presentations shed light on the promising progress made in their Phase 1 studies of ALG-055009 and ALG-000184. The findings shared at this renowned medical conference mark a significant milestone in combating unmet medical needs in these critical areas.Meeting Highlights:Aligos Therapeutics presented three oral presentations and one poster presentation, highlighting their latest clinical...
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Revolution Medicines Inc operates as a biopharmaceutical company that focuses on discovering and developing new drugs to target cancers and other diseases caused by defects in cellular signaling. Their business model involves leveraging their expertise in precision oncology and molecular biology to identify novel drug candidates and advance them through preclinical and clinical development stages.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Intensity Therapeutics Inc's business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.
Sources:
Aligos Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aligos Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
